The combination treatment of the GLS inhibitor CB-839 with capecitabine showed dramatically increased therapeutic efficiency in CRC cells with PIK3CAp110α mutations in both preclinical and clinical trials [204]. Here, GLS is linked to colorectal carcinoma.